2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

Ankle–brachial index Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]AtherosclerosisVol. 294PreviewIn row 4 of Table 3, ‘should’ should read as ‘may’; Full-Text PDF Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]AtherosclerosisVol. 292PreviewThe Publisher regrets that the Author's name C. Koskinas was spelt incorrectly in the originally published version of this paper. The name has therefore been spelt correctly above. Full-Text PDF Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitorsAtherosclerosisVol. 309PreviewThe latest ESC/EAS guidelines for the management of dyslipidaemias have lowered the low-density lipoprotein cholesterol (LDL-C) target in the very high-risk patients below 55 mg/dL [1.4 mmol/L] [1]. This subgroup includes heterozygous familial hypercholesterolaemia (heFH) patients with cardiovascular disease (CVD) as well as heFH patients with another major risk factor, i.e. smoking, diabetes mellitus, etc. The previous LDL-C target for heFH patients without CVD was <100 mg/dL (2.6 mmol/L), while in the setting of CVD was <70 mg/dL (1.8 mmol/L). Full-Text PDF The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patientsAtherosclerosisVol. 292PreviewThe recently published ESC/EAS guidelines for the management of dyslipidaemias have lowered the low-density lipoprotein cholesterol (LDL-C) target in the very high risk patients below 55 mg/dL [1.4 mmol/L] [1]. The drug of choice for achieving this target is high-intensity statin to the highest tolerated dose. If the goal is not achieved, the addition of ezetimibe is recommended first, and then the addition of a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i), if LDL-C remains above target. Full-Text PDF Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: Results from the Rotterdam StudyAtherosclerosisVol. 299PreviewIn the recently published update of the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) clinical practice guidelines for the management of dyslipidaemias, indications for lipid-lowering treatment have been expanded to those at lower cardiovascular risk and with lower LDL levels, as well as to those 65–75 years of age, according to their level of predicted cardiovascular disease (CVD) risk [1,2]. To what extent these updates affect treatment recommendations at population level is unclear. Full-Text PDF Translating science into guidance on the management of dyslipidaemiasAtherosclerosisVol. 315PreviewDifferent approaches have been proposed and used in the past to improve preventive cardiology in clinical practice; among these, the use of guidelines on cardiovascular disease prevention in clinical practice is one example. Recommendations on the most appropriate management of dyslipidaemias are a cornerstone in this respect. Evidence-based guidelines have been developed on this issue as a tool to help clinicians in clinical decision making to prevent atherosclerotic cardiovascular disease (ASCVD). Full-Text PDF Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemiaAtherosclerosisVol. 324PreviewFamilial hypercholesterolemia (FH) is a genetic disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) from birth and an increased risk of premature cardiovascular disease. Full-Text PDF